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Abstract
The development of human organoid culture models has led to unprecedented opportunities to generate self-
organizing, three-dimensional miniature organs that closely mimic in vivo conditions. The ability to expand, culture,
and bank such organoids now provide researchers with the opportunity to generate next-generation living biobanks,
which will substantially contribute to translational research in a wide range of areas, including drug discovery and
testing, regenerative medicine as well as the development of a personalized treatment approach. However, compared
to traditional tissue repositories, the generation of a living organoid biobank requires a much higher level of
coordination, additional resources, and scientific expertise. In this short review, we discuss the opportunities and
challenges associated with the generation of a living organoid biobank. Focusing on human intestinal organoids, we
highlight some of the key aspects that need to be considered and provide an outlook for future development in this
exciting field.
Introduction
A vast amount of human tissue is being collected for
routine clinical purposes on a daily basis, and often, only a
fraction of the available material is required. It has long
been recognized that the prospective storage of such
excess tissue in the form of biobanks or tissue banks
provides extensive opportunities for future research stu-
dies1–6. Indeed, many ground-breaking discoveries in both
basic and translational biomedical research have benefitted
from the analyses of human tissue stored in large bio-
banks. Importantly, the value of such tissue banks is
directly associated with the quality of their organization,
which includes the detailed documentation of patient
information as well as sample processing and storage.
Major progress has been made in this field, leading to the
development of large, highly sophisticated biobanks7–10.
However, a major limitation of stored tissue is the inability
to perform functional experiments, which are required for
many areas, particularly in translational research. The
development of human organoid culture models has
provided researchers with unprecedented opportunities to
generate miniature organs that closely mimic in vivo
anatomy and pathophysiology and retain patient-specific
characteristics11. To date, organoids have been success-
fully generated from a wide range of human tissues,
including the entire intestinal tract12–17. Indeed, since the
development of the first organoid culture model from the
mouse small intestine approximately one decade ago18,
substantial progress has been made in this area19–21.
Although the majority of topics discussed in this review
will equally apply to any organoid biobank, we will focus
on the human intestine based on our own experience in
this field.
Intestinal organoids are defined as self-organizing three-
dimensional structures that closely mimic the in vivo
situation. In principle, they can be generated either from
pluripotent stem cells (e.g., induced pluripotent stem cells
(iPSCs) or embryonic stem cells (ESCs)) or adult stem
cells22–24. The latter is located in the crypts of the
intestinal epithelium and, upon provision of the
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appropriate scaffold and culture conditions that mimic
the stem cell niche, will self-organize into mature intest-
inal epithelial organoids (IEOs), which contain all epi-
thelial cell subsets structured in a crypt villus axis. To
date, IEOs have been successfully generated from all gut
segments of the human intestinal tract, and several studies
have shown that organoids display gut segment-specific
features in vitro25–27. Furthermore, increasing evidence
suggests that patient-derived IEOs retain donor-specific
properties such as age, gender, and disease-associated
differences9,28,29. As a result, IEOs provide scientists with
unprecedented opportunities to use these models as
highly versatile translational research tools. Areas of
clinical relevance include but are by no means limited to
the development of novel therapeutics, testing of existing
drugs with an aim to personalize treatment based on
responses as well as the use in regenerative medicine
(Fig. 1a)11,30–32.
Importantly, IEOs can be expanded in vitro over pro-
longed time periods and frozen stocks can be generated at
any time during this process. This phenomenon allows
the generation of living biobanks and biorepositories that
can be shared with researchers across the globe and in
particular those who do not have access to human tissue
samples (Fig. 1b). However, despite the extraordinary
progress in the field of human IEOs over the last decade,
in regard to translating science into patient care, addi-
tional caution and stringent quality control procedures
are critical first steps. In the following, we will briefly
summarize examples of existing human organoid bio-
banks and highlight considerations for generating and
distributing IEOs as part of a biobank or biorepository.
Finally, we will provide an outlook on future develop-
ments and key strategic goals for the field. We will pri-
marily focus on mucosa-derived IEOs, as our group has
extensive expertise in this field. Nevertheless, most
aspects we discuss will also apply to iPSC-derived gut
organoids, and we therefore will not distinguish between
them unless otherwise specified.
Existing human intestinal organoid biobanks
The major value of generating organoid biobanks for
translational research purposes has long been recognized
and is reflected in the rapidly increasing number of stu-
dies reporting on the successful establishment of large
patient-derived, living biobanks. Interestingly, the vast
majority of such sample collections have been derived
from patients diagnosed with various malignancies,
including those affecting the gastrointestinal tract.
Examples include colorectal cancer, metastatic colorectal
and esophageal cancer, gastric cancer, pancreatic
cancer, and advanced rectal cancer (summarized in
Table 1)9,28,29,33–38. In all of these cases, the generation of
patient-derived biobanks included a detailed description
of clinical phenotype and patient records, characteristics
of samples used to generate organoids (such as macro-
scopic and/or histological appearance), as well as mole-
cular profiling of both the tissue of origin and/or the
resulting organoid cultures. Furthermore, most studies
also provide evidence for generated organoids to recapi-
tulate patient and disease-specific pathophysiological
processes, thereby validating them as translational
research tools9,28,29. Importantly, several studies have
highlighted the ability of generated organoids to perso-
nalize treatment by demonstrating a patient-specific
response to existing treatments34,35.
In contrast to reports on malignancies, only a limited
number of studies have been able to demonstrate the
value of living organoid biobanks for other GI-related
conditions. This phenomenon is in part due to the pre-
sence of genetic alterations in malignant tissue which are
faithfully retained in organoid cultures and impact cellular
function. Indeed, cystic fibrosis (CF) represents another
example of a genetic, nonmalignant condition for which
the value of patient-derived organoids as translational
tools to stratify treatment has been demonstrated. CF is
caused by various mutations in the CF transmembrane
conductance regulator (CFTR) gene39. Human IEOs
derived from rectal biopsies of CF patients have shown a
strong correlation with in vivo drug responses by using a
forskolin-induced swelling assay in vitro40. Based on these
discoveries, a living organoid biobank was generated
representing over 600 patient-derived organoid cultures36.
Notably, all generated organoid lines were shown to retain
patient-specific mutations in the CFTR gene, some of
which could be corrected using SpCas9-induced DNA
template recombination or SpCas9-adenine base edit-
ing36,41. The latter fact further highlights the use of gen-
ome editing to further enhance the value of organoid
cultures as translational research tools.
One of the most extensive organoid biobanks was
established by the The Hubrecht Institute, the University
Medical Center Utrecht, and the Royal Netherlands
Academy of Arts and Sciences (KNAW) as part of
Hubrecht Organoid Technology (HUB, https://
huborganoids.nl/). The collection contains more than
1000 organoid lines generated from different organs and
diseases, including breast, colon, head, neck, intestine,
liver, lung, ovarian, and pancreatic tumors, as well as a
large number of intestinal organoids derived from CF
patients. Genetic and histological data of all lines are
available along with detailed information about the sen-
sitivity to specific drugs for treatment strategies in the
case of CF patient-derived organoids.
In addition to academic institutions, organoid biobanks
have been established by commercial entities such as
Sigma-Aldrich, the American Type Culture Collection
(ATCC, (www.attc.org)), Cellesce (https://cellesce.com)
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and DefiniGEM (https://www.definigen.com/products/
intestinal/organoid/). These collections offer a wide
range of human organoids derived from either iPSCs or
primary tissues (Table 1) covering both healthy donors
and patients with established diseases. Detailed informa-
tion on both generated organoid cultures and donors is
also available and includes molecular profiling, the results
of drug screening, and the presence of specific genetic
mutations in some instances. A proportion of organoid
lines available via these biobanks were generated from
iPSCs, further extending the experimental repertoire and
potential applications of cultures available to researchers.
Fig. 1 Establishment of an organoid biobank and its applications. a Applications for next-generation organoid biobanks in translational research.
b Basic workflow for the generation of an organoid biobank. Key areas requiring careful consideration and detailed documentation include (1) donor
information, (2) tissue of origin, (3) culture methodology and passage number, (4) generation of frozen stocks, (5) documentation of organoid growth
and morphology, (6) molecular profiling of organoids and/or primary tissue, and (7) relevant clinical information. All images were created with
BioRender.com.
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In summary, the number of organoid biobanks and
repositories has been increasing in recent years, with a
large proportion of disease-related collections focused on
malignant and/or genetically well-defined conditions.
Important features of organoid biobanks
Despite major progress made in this field and the high
quality of human organoid biobanks established to date,
several areas require consideration to further improve the
value of living organoid biobanks in the future. In the
following, we will summarize some of the key aspects that
are critical for the generation of a living organoid biobank
to enhance their value for translational research.
Patient and sample details
One of the most important advantages of patient-derived
organoids is the fact that these cultures retain the molecular
as well as functional characteristics of their donors26,28.
Hence, providing detailed donor information directly cor-
relates with the utility of generated organoids. In addition to
basic characteristics such as gender, age, ethnic background,
and potential disease, additional information such as med-
ication, diet, family history of any medical conditions, or the
presence of gastrointestinal symptoms are all highly rele-
vant to a wide range of possible research questions. Fur-
thermore, prospective documentation of disease outcome
and treatment history, including response to individual
treatments, will allow the correlation of organoid-derived
molecular signatures or potential functional differences
with clinical phenotype. In other words, the documentation
of patient details forms the basis for the use of organoids as
tools to develop personalized treatment approaches and/or
clinical biomarkers (Fig. 1b).
Similarly, the type of tissue samples used to generate
IEOs is also critically important. The tissue samples used
vary from mucosal biopsies (obtained during routine
clinically indicated endoscopy) and surgical resection
material to deceased tissue donation. Each of these tissue
types may impact the cellular function of generated
organoids even if samples were obtained from the same
organ/gut segment. In addition, the time from obtaining
tissue to initiating organoid cultures, including specifica-
tion about possible tissue storage, may also impact
downstream analyses and should therefore be recorded.
Finally, the macroscopic and histological appearance of
the intestinal mucosa from which the tissue sample was
taken provides highly valuable information on the in vivo
microenvironment at the time of sampling and is there-
fore relevant for the interpretation of experimental results
obtained from generated organoids. Providing repre-
sentative histological images (e.g., hematoxylin and eosin
stains) of the original tissue used to generate organoids
further enhances the value of the generated lines for
future applications.
We would like to highlight the fact that there is cur-
rently a lack of published evidence to support the possible
impact of the factors mentioned above on generated
organoids. However, based on our experience and
unpublished data, we believe that these factors are indeed
critically important, and unfortunately, many existing
studies lack the required information. Hence, prospective,
detailed documentation will help to address these
important issues in the future and aid the interpretation of
generated data as part of published work.
In summary, the value and future use of an organoid
biobank for basic and translational research studies cri-
tically depend on the information provided on donor and
tissue samples used to generate cultures. Despite the
major complexities and additional work required to
record such details, the increase in value will no doubt
outweigh the invested resources.
Culture conditions and documentation of growth
The initiation and long-term culture of human IEOs
were first described by Sato et al.15 just over one decade
ago. Since then, major progress has been made with
regard to optimizing existing protocols. Although the
basic culture conditions used are largely comparable
between studies and research groups, even subtle varia-
tions could lead to substantial differences in organoid
phenotype, growth or any downstream analyses per-
formed. One example of such variation is the source of
Wnt3a, which is a key component of human IEOs culture
medium42,43. Although Wnt3a is commercially available
as a recombinant protein, its use in the culture of human
gut organoids has been reported to be insufficient, as it
results in reduced organoids growth44. As a result, many
studies report the use of conditioned medium-producing
cell lines as a source of Wnt3a45,46. However, although
this approach appears to be superior to the use of
recombinant protein, based on our experience, there is
substantial variation in batches of conditioned medium,
which may impact on organoid growth and/or molecular
processes. More recently, a new next-generation surro-
gate Wnt ligand able to bind both the Wnt receptor
(Frizzled) and coreceptors (Lrp5/6) was developed and
shown to support the long-term growth of human IEOs47.
The use of this next-generation recombinant Wnt sur-
rogate will likely improve the reproducibility of organoid
work as information on specific concentrations used can
be provided. Another example of possible variation in
organoid culture comes with the use of different scaf-
folding reagents to support culture growth. Matrigel,
derived from mouse sarcoma, is among the most fre-
quently used extracellular matrix scaffolds and has been
shown to adequately support human gut organoid growth
and 3D self-organization in many studies48,49. However,
the composition of Matrigel remains ill-defined and
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appears to display substantial batch variation, which could
impact on reproducibility and comparability of stu-
dies50,51. Alternative options include animal-derived gel
matrixes such as collagen type I and the more recently
developed synthetic scaffolds using artificial hydrogels
such as polyethylene glycol (PEG), which showed com-
parable results to those of Matrigel in supporting orga-
noids growth52,53. The latter benefits from a clearly
defined composition and adjustable mechanical proper-
ties, which may reduce the risk of technical variation
among studies54,55. These examples highlight the need for
organoid repositories to provide detailed documentation
of culture conditions used by paying particular attention
to detail, as minor changes can lead to substantial dif-
ferences in the results generated.
Regardless of the culture conditions used, documenting
organoid growth and structure is critically important and
highly valuable. This process can be performed using light
microscopy at key stages, including budding stages follow-
ing the first initiation of cultures, immediately after sub-
culturing, and before frozen stocks are being generated.
Information on how many organoids are frozen is also
helpful for downstream users and should be considered as
standard practice. Similarly, information is routinely pro-
vided when sharing cell lines, such as details on regular
testing of tissue culture medium for contaminants56,57.
The number of passages and culture duration are also
critically important and should therefore be recorded.
Although human IEOs can be kept in culture for months,
even years, the potential impact on cellular phenotype
remains largely unknown. Indeed, it is highly likely that
artificial culture conditions and the lack of certain external
stimuli present in vivo (e.g., cell-cell signaling, microbiota,
exposure to nutrients, etc.) may impact epithelial cell
function and/or alter molecular profiles. Hence, the gen-
eration of robust evidence on the impact of culture duration
on human organoids with regard to phenotypic changes
(both transient and/or permanent) should be considered a
priority in the field. Moreover, documentation of culture
duration and passage number must form an essential part
of the information provided (Fig. 1b).
Cryopreservation of tissue for organoid generation
The ability to generate organoids from cryopreserved
human tissue has substantially increased the value of
samples obtained both for routine clinical care and for
specific research settings. A number of protocols have
been published that allow cryopreservation of tissue
samples followed by successful establishment of organoids
even after long-term storage58–60. In principle, these
protocols require tissue samples to be transferred to
freezing medium followed by a gradual reduction in
temperature down to −80 °C and transfer to liquid
nitrogen storage59,61. Success rates for the generation of
organoids from frozen tissue are likely to be lower than
those for fresh tissue; however, based on our own
experience, up to 80% of adequately cryopreserved gut
biopsy samples will give rise to viable organoids lines59,62.
Importantly, these methods will further broaden the
application of human organoid technologies and the
opportunity for the generation of large living biobanks, as
samples can be obtained from patients treated at smaller
hospitals that do not have the required research infra-
structure to initiate organoid cultures themselves.
However, although based on our experience, organoids
generated from frozen tissue samples appear to display
the same growth characteristics and morphology as cul-
tures derived from fresh tissue, a freeze-thaw cycle and
long-term storage could impact on the cellular function of
the generated organoid cultures. Further studies are
needed to address this important issue. Thus, detailed
information on freezing methods and storage duration
should be routinely recorded.
Molecular profiling of human IEOs
In addition to providing detailed information on donors,
tissues, and organoid culture, generating molecular pro-
files of stored IEOs and/or the primary tissue used to
generate these cultures can vastly increase their future
value for translational research studies (Fig. 1b). As out-
lined above, numerous studies have demonstrated the
application of organoids in translational research studies
by linking organoid function to molecular profiles, mainly
genetic profiles (Table 1)34,63–65. However, in contrast to
the use of genotype to subclassify organoids and stratify
possible treatments, other molecular profiles are more
likely to change during in vitro culture, making it more
challenging to identify a potential correlation with disease,
phenotype or response to treatment. For example, tran-
scriptional profiles generated from human IEOs will vastly
vary according to a number of factors, such as culture
duration following initiation or splitting, the level of dif-
ferentiation (i.e., profiled in maintenance medium versus
in vitro differentiation) in culture medium, and scaffolds
and growth factors used. Other molecular signatures/
mechanisms, such as DNA methylation, might also be
useful, as they have been shown to be highly stable in
culture and retain both gut segment, age, and disease-
specific alterations in human IEOs25,66. Future studies will
be able to elucidate these issues further and help to
streamline the molecular profiling of organoid biobanks in
the future. Currently, the provision of genotypes derived
from the original tissue used to generate organoids will
substantially increase their future use.
Ethical considerations
Although next-generation living organoid biobanks
have substantial potential and provide unprecedented
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opportunities for future translational research, they raise
numerous ethical issues beyond those that apply to sharing
primary human tissue samples. Developments in this
important area are ongoing, and due to the complexity of
the subject, providing further details is beyond the scope of
this review article. However, we refer the interested reader to
a number of excellent articles on this topic which highlight
some of the key issues including the difficulties in balancing
maximizing the benefit of organoid culture technology by
making them widely available and providing detailed
accompanying information whilst at the same time pro-
tecting donor identity6,67–71. While close collaboration with
pharmaceutical companies forms a vital step in the process
of translating any academic discoveries from the bench to
the bedside, the prospect of profit-making from human
tissue donated for academic research is ethically contentious
and likely to raise concern among the wider public72.
These are only some of the major ethical issues that
require urgent and careful attention to ensure the timely
development of sound guidelines for scientists, clinicians,
and other stakeholders.
Future directions and conclusions
The storage and subsequent sharing of human orga-
noid cultures as part of next-generation biobanks have
the potential to substantially increase their value and
provide major opportunities for basic and translational
research. However, the complexities involved in both
generating and culturing human organoids as well as
storing not only the tissue but also relevant information
provide significant additional challenges. Furthermore,
given that organoid models are being rapidly developed
and improved, validation and quality control studies are
urgently needed to inform best practice and support the
development of widely accepted protocols. Key areas
include the potential impact of long-term in vitro cul-
turing on molecular signatures and cellular function as
well as more detailed validation studies aiming to
determine the degree to which organoids retain disease-
specific features in culture. The potential impact of long-
term storage and/or freeze-thaw cycles as fundamental
aspects of biobanking must be further explored. Finally,
the establishment of clear ethical guidelines that cover
areas such as commercialization, patient consent, and
the use of organoids for future, non-specified research
are needed to ensure the will and privacy of donors are
protected.
In conclusion, despite major challenges associated with
the generation of next-generation living organoid bio-
banks, their future use in translational biomedical
research is likely to contribute to many groundbreaking
discoveries. A collaborative and well-organized effort
from the scientific community is required to ensure timely
developments in this exciting area.
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